Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Methadone+BEM/RZR · 1 trial · 1 indication
Cmax
Cmax
| Arm | Type | Description |
|---|---|---|
| (n=16) buprenorphine/naloxone + BEM/RZR | EXPERIMENTAL | - |
| (n=16) methadone + BEM/RZR | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Buprenorphine/Naloxone + BEM/RZR | DRUG | Day -5 to Day -1:buprenorphine/naloxone as individualized QD doses up to 24mg/6mg. Day 1 to Day 5:Individualized QD doses of buprenorphine/naloxone. Day 6 to Day 12:Individualized QD doses of buprenorphine/naloxone + BEM 550mg/RZR 180mg QD. Day 13 Individualized QD doses of buprenorphine/naloxone. |
| Methadone +BEM/RZR | DRUG | Day -5 to Day -1:methadone individualized QD doses: 30-150mg. Day 1 to Day 5:Individualized QD does of methadone. Day 6 to Day 12:Individualized QD doses of methadone + BEM 550mg/RZR 180mg QD. Day 13 Individualized QD doses of methadone. |
Inclusion Criteria: * Must agree to use acceptable contraceptive methods through at least 90 days after the last dose of study drug. * Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/ m2. * Willing to comply with the study requirements and to provide written informed consent. Ex...
Methadone+BEM/RZR is an investigational combination being studied in a Phase 1 clinical trial for use in healthy volunteers. The study is a drug-drug interaction trial evaluating the combination of bemnifosbuvir/ruzasvir (BEM/RZR) with buprenorphine/naloxone or methadone. It is not approved for any indication and remains in clinical development.
Methadone+BEM/RZR is being developed by Atea Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol AVIR. The company is conducting a Phase 1 clinical trial to evaluate the drug-drug interaction between BEM/RZR and methadone or buprenorphine/naloxone in healthy volunteers.
Methadone+BEM/RZR is in Phase 1 clinical development. The ongoing trial, NCT07314346, is a Phase 1 study that is currently recruiting participants. The drug is investigational and has not been approved by regulatory authorities for any use.
Methadone+BEM/RZR is being evaluated in one active Phase 1 clinical trial, NCT07314346, titled "Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone." The trial is recruiting 32 healthy volunteers in the United States and is not randomized or double-blind.
Yes, Methadone+BEM/RZR is the same as Methadone +BEM/RZR. Both names refer to the combination of methadone with bemnifosbuvir/ruzasvir (BEM/RZR), which is being studied in a Phase 1 drug-drug interaction trial in healthy volunteers.